gabexate has been researched along with Bile Duct Cancer in 1 studies
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakanuma, S | 1 |
| Tajima, H | 1 |
| Okamoto, K | 1 |
| Hayashi, H | 1 |
| Nakagawara, H | 1 |
| Onishi, I | 1 |
| Takamura, H | 1 |
| Kitagawa, H | 1 |
| Fushida, S | 1 |
| Tani, T | 1 |
| Fujimura, T | 1 |
| Kayahara, M | 1 |
| Ohta, T | 1 |
| Wakayama, T | 1 |
| Iseki, S | 1 |
| Harada, S | 1 |
1 other study available for gabexate and Bile Duct Cancer
| Article | Year |
|---|---|
Tumor-derived trypsin enhances proliferation of intrahepatic cholangiocarcinoma cells by activating protease-activated receptor-2.
Topics: Adult; Aged; Aged, 80 and over; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocell | 2010 |